Reduced quality of life in children with gastro-oesophageal reflux disease

M Marlais1, J R Fishman, J Köglmeier

  • 1Department of Paediatric Gastroenterology, Chelsea and Westminster Hospital, London, UK. mm1305@ic.ac.uk

Insights

Quality of life (QoL) is significantly reduced in children with Gastro-oesophageal reflux disease (GORD) compared to healthy peers and those with Inflammatory Bowel Disease (IBD). This study assessed QoL in pediatric patients with GORD.

Area of Science:

  • Pediatric Gastroenterology
  • Quality of Life Research
  • Clinical Pediatrics

Background:

  • Gastro-oesophageal reflux disease (GORD) is a common condition in children.
  • Assessing the impact of chronic pediatric conditions on Quality of Life (QoL) is crucial for comprehensive patient care.
  • Limited data exists on self-reported QoL specifically for children diagnosed with GORD.

Purpose of the Study:

  • To evaluate the self-reported Quality of Life (QoL) in children aged 5-18 diagnosed with Gastro-oesophageal reflux disease (GORD).
  • To compare the QoL of children with GORD against disease-matched controls (Inflammatory Bowel Disease, chronic constipation) and healthy children.
  • To provide insights into the patient-reported outcomes for pediatric GORD.

Main Methods:

  • A prospective study involving 184 children (aged 5-18) attending a tertiary pediatric gastroenterology clinic.
  • Participants included children with GORD, chronic constipation, Inflammatory Bowel Disease (IBD), and healthy controls.
  • The validated Pediatric Quality of Life Inventory (PedsQL) generic assessment (self-report) was administered, measuring physical, emotional, social, and school domains.

Main Results:

  • Children with GORD (n=40) reported significantly lower QoL (mean score 74) compared to healthy children (n=41, mean score 84) and children with IBD (n=59, mean score 82).
  • QoL in the GORD group was comparable to children with chronic constipation (n=44, mean score 74).
  • The PedsQL scores ranged from 0 to 100, assessing multiple domains of daily functioning.

Conclusions:

  • Self-reported Quality of Life (QoL) is significantly diminished in pediatric patients with Gastro-oesophageal reflux disease (GORD) attending specialist clinics.
  • Children with GORD experience a lower QoL than both healthy children and those with Inflammatory Bowel Disease (IBD).
  • These findings highlight the substantial impact of GORD on the well-being of affected children.
Abstract

Related Concept Videos

Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Gastroesophageal Reflux Disease01:25

Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is the backward flow of stomach contents (acid, pepsin, or bile) into the esophagus, causing mucosal inflammation known as esophagitis. It results from failure of antireflux mechanisms, mainly the lower esophageal sphincter (LES), influenced by mechanical and physiological factors.Etiology and Risk FactorsGERD develops when LES function is weakened or when intra-abdominal pressure increases. Risk factors include aging, obesity, and sliding hiatal hernia,...
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology01:29

Gastroesophageal Reflux Disease I: Meaning and Pathophysiology

Gastroesophageal Reflux Disease (GERD) involves the recurrent backflow of the stomach or duodenal contents into the esophagus, leading to troublesome symptoms and potential esophageal mucosal damage. Although GERD is often referred to as a disease, it is more accurately described as a syndrome, as it encompasses a range of symptoms and complications rather than a singular pathological entity, impacting a large number of individuals as the most prevalent upper gastrointestinal problem. Roughly...
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...